SCHEMBL3016045

SCHEMBL3016045

Cc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(C(C)(C)C)cc4)CC3)n2)cc1C

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DNM1L O00429 6/20 0.34
GBA1 P04062 1/20 0.34
NAMPT P43490 4/20 0.33
NPSR1 Q6W5P4 2/20 0.32
ALDH1A1 P00352 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
KMT2A Q03164 2/20 0.32
CYP1A2 P05177 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32
CYP2C19 P33261 1/20 0.32
HTT P42858 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
MEN1 O00255 1/20 0.32
HSD11B1 P28845 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014285 0.91 GBA1 (0.41) DNM1LGBA1NAMPTNPSR1ALDH1A1
SCHEMBL3014372 0.90 GBA1 (0.41) DNM1LGBA1NPSR1ALDH1A1SMN1; SMN2
SCHEMBL3013632 0.89 SMN1; SMN2 (0.36) DNM1LGBA1NAMPTNPSR1ALDH1A1
SCHEMBL3016829 0.89 DNM1L (0.35) DNM1LGBA1NAMPTNPSR1ALDH1A1
SCHEMBL3002167 0.89 MAPT (0.37) DNM1LGBA1NAMPTNPSR1ALDH1A1
SCHEMBL3011437 0.89 HTR2A (0.39) DNM1LGBA1ALDH1A1SMN1; SMN2KMT2A
SCHEMBL3012528 0.89 DNM1L (0.37) DNM1LGBA1NPSR1ALDH1A1SMN1; SMN2
SCHEMBL3014922 0.88 LMNA (0.37) DNM1LNAMPTNPSR1ALDH1A1SMN1; SMN2
SCHEMBL3009616 0.88 CACNA1G (0.35) DNM1LGBA1NAMPTSMN1; SMN2CYP2C9
SCHEMBL3006460 0.88 GBA1 (0.37) DNM1LGBA1NPSR1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA DNM1L 180/4885GBA1 4/4885NAMPT 2273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.